Sermorelin
Sermorelin Acetate
Potential Benefits
- Stimulates natural GH production through the pituitary gland
- Has prior FDA-approval history, providing more clinical safety data than many peptides
- May support improved sleep quality and recovery
- Research suggests potential benefits for body composition over time
- May support bone density maintenance in aging populations
Recommended Starting Dose
200-300 mcg subcutaneously at bedtime
Based on published research protocols. Not a prescription.
Dosing Protocol
Typically injected subcutaneously once daily at bedtime to align with natural GH secretion patterns. Doses range from 200-500 mcg. Cycles of 3-6 months are common in clinical settings, sometimes with periodic breaks.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Sleep improvements may appear within the first 2-4 weeks. Body composition and skin quality changes typically take 3-6 months of consistent use.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Injection site reactions (pain, redness, swelling)
- Flushing
- Headache
- Dizziness
- Potential for antibody formation with prolonged use, reducing efficacy
- Transient hyperactivity in some individuals
More in Growth Hormone
CJC-1295 (no DAC) / Mod GRF 1-29
CJC-1295 without DAC
CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone in a pulsatile fashion, mimicking the body's natural rhythm. It is often paired with a GHRP like Ipamorelin for synergistic effects.
CJC-1295 DAC
CJC-1295 with Drug Affinity Complex
CJC-1295 with DAC is a long-acting GHRH analog that includes a Drug Affinity Complex, which binds to albumin in the blood and extends its half-life to approximately 6-8 days. This results in sustained elevation of growth hormone levels rather than pulsatile release. It was developed by ConjuChem Biotechnologies.
Ipamorelin
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor to stimulate growth hormone release from the pituitary gland. It is considered one of the milder GH secretagogues, producing a targeted GH pulse without significant increases in cortisol, prolactin, or appetite. It is frequently combined with CJC-1295 (no DAC).
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.